Definitive Healthcare reported second quarter results on August 10, and the print carried several facts that together define the current position. Revenue for the quarter came in at $55.2 million, down meaningfully from the year earlier. The first half total was also down over the same period. Management guides to a full year revenue decline, a rare explicit negative outlook for a Nasdaq listed software business. The interim disclosure also revealed a Nasdaq minimum bid compliance notice. The cure deadline is December 15, 2026. A first quarter restructuring plan cut approximately 40 positions. Management disclosed professional fees tied to the evaluation of strategic, financial, tax, and capital structure alternatives. The Turbo AI platform enters a select customer pilot in the third quarter.
The question the disclosure answers is whether the healthcare data franchise can outgrow its own renewal problems. The principal variable is net dollar retention, which the company no longer discloses quarterly. Customer count fell from roughly 2,400 to 2,200 in twelve months. Enterprise Customers, defined as accounts above six figures of annual recurring revenue, declined by 33 to 477. Two consecutive goodwill impairments zeroed out the carrying value of the asset. The fiscal 2025 charge was $196.1 million. The first quarter 2026 charge was $197.2 million. The company has taken impairment charges in each of the last three fiscal years.
The broader framing is a sub $160 million market capitalization for a business with roughly $241.5 million of trailing revenue. Cash and short-term investments sit against term loan principal of $160.6 million, and the current remaining performance obligation has contracted to $149.9 million. The equity is being asked to price a turnaround in retention, a Nasdaq cure, and an AI pilot, while management signals an active search for strategic alternatives. The disclosure cadence over the next two quarters, anchored by the December 15 listing deadline, is the data that resolves the direction.